Nearly 30 million patients in the United States suffer from either type 1 or type 2 diabetes. Hypoglycemia is a common and potentially life-threatening side effect of diabetes treatment. Clinical implications of hypoglycemia include acute risk of cognitive impairment, seizure, cardiovascular events, brain damage or even death, as well as long term risks of accelerated dementia. The progressive loss of hypoglycemic awareness, hypoglycemic unawareness, impairs recognition of the early signs of low blood sugar, increasing the severity of acute complications and the need for hospitalization. Current methods for management of severe hypoglycemia include intravenous dextrose infusion or intramuscular injection of glucagon. However, these methods require that an emergency source of medication is always available near the patient, and necessitate reliance on caregivers who may not be well trained to administer these treatments. A closed-loop implantable drug delivery system (IDDS) that releases anti-hypoglycemic drugs precisely in response to low blood glucose levels, and is small enough to be implanted with minimal invasiveness, could substantially improve hypoglycemia management. The goal of this project is to develop novel technologies to make such an IDDS a reality. The proposed IDDS is the first ultrasonically powered implant platform for precision drug delivery that is minimally invasive and enables fully programmable, personalized, and closed-loop drug delivery to treat severe hypoglycemia. The IDDS utilizes electroresponsive polypyrrole nanoparticles (PPy NPs) to store the required drugs. When electrically stimulated, the PPy NPs change shape and size, thereby releasing their drug cargo. The IDDS is wirelessly powered using ultrasound which enables miniaturization of the implants for minimal invasiveness, and safe operation in the body. Closed-loop control will be implemented in order to release the drugs only when a low or rapidly falling glucose level is detected by a commercial glucose monitor. The objective will be reached by pursuing the following three specific aims: (1) Under Aim I, the size and composition of the nanoparticles will be optimized for efficient release of anti-hypoglycemic drugs. Our current models for enhancement of the stability of the drugs when attached to the nanoparticles will also be verified and optimized in vitro and in vivo in mouse models. (2) Aim II will entail development of the packaged mm-sized IDDS implant, integration of a commercial glucose monitor into the system, and in vitro validation of closed-loop functionality. (3) Under Aim III, in vivo tests in mice with induced hypoglycemia will be performed to optimize therapeutic reversal of hypoglycemia and subsequently with the integrated implant platform to test the feasibility of using the device to treat diabetic hypoglycemia. This project is significant as its successful completion could not only lead to a paradigm shift in how hypoglycemia is treated in the future, but also improve the treatment of other chronic diseases that require programmed, precise and localized drug delivery.

Public Health Relevance

A major contributor to the morbidity and mortality of diabetes is treatment-related hypoglycemia which leads to approximately 300,000 emergency department visits per year in the United States. The goal of the proposed project is to develop the technology required for a minimally invasive implantable drug delivery system (IDDS) that is wirelessly powered, programmable, and capable of releasing anti-hypoglycemic agents in response to low blood glucose levels. Such a device can prevent episodes of severe hypoglycemia, thereby reducing morbidity, mortality and overall health care costs.

Agency
National Institute of Health (NIH)
Institute
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Type
Research Project (R01)
Project #
5R01EB025867-02
Application #
9663301
Study Section
Instrumentation and Systems Development Study Section (ISD)
Program Officer
Lash, Tiffani Bailey
Project Start
2018-04-01
Project End
2022-01-31
Budget Start
2019-02-01
Budget End
2020-01-31
Support Year
2
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Stanford University
Department
Engineering (All Types)
Type
Biomed Engr/Col Engr/Engr Sta
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94304
Chang, Ting Chia; Weber, Marcus J; Charthad, Jayant et al. (2018) End-to-End Design of Efficient Ultrasonic Power Links for Scaling Towards Submillimeter Implantable Receivers. IEEE Trans Biomed Circuits Syst 12:1100-1111
Neumann, S Ephraim; Chamberlayne, Christian F; Zare, Richard N (2018) Electrically controlled drug release using pH-sensitive polymer films. Nanoscale 10:10087-10093